Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol, a development stage blood purification technology; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone732-329-8885
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.50 million
Profitability
Miscellaneous
Employees125
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions
What is Cytosorbents' stock symbol?
Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."
How were Cytosorbents' earnings last quarter?
Cytosorbents Corp (NASDAQ:CTSO) posted its earnings results on Thursday, March, 7th. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.04. The medical research company had revenue of $6.08 million for the quarter, compared to analyst estimates of $6.08 million. Cytosorbents had a negative return on equity of 94.30% and a negative net margin of 76.48%. View Cytosorbents' Earnings History.
When is Cytosorbents' next earnings date?
What price target have analysts set for CTSO?
3 brokers have issued 12 month price objectives for Cytosorbents' shares. Their predictions range from $15.00 to $18.00. On average, they anticipate Cytosorbents' share price to reach $16.00 in the next twelve months. This suggests a possible upside of 133.6% from the stock's current price. View Analyst Price Targets for Cytosorbents.
What is the consensus analysts' recommendation for Cytosorbents?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytosorbents.
What are Wall Street analysts saying about Cytosorbents stock?
Here are some recent quotes from research analysts about Cytosorbents stock:
- 1. Maxim Group analysts commented, "Cytosorbents reported 4Q18 with $5.5M in product sales, up 7% from $5.1M in 3Q18 and 30% from $4.2M y/y. For the year, revenue was $22.5M, a new record for the company and the first time revenue exceeded $20M. The company reported net income of ($5.4M) and $22.4M in cash." (3/8/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of CytoSorbents and our 12-month price target of $15.00 per share. We derive our price target based on the average of two valuation methods: 1) price-sales multiple using 7x 2025 sales estimate discounted at 12%; and 2) price-earnings multiple using 25x 2025 earnings estimate discounted at 12%. (1) commercial; (2) partnership; (3) clinical; (4) financial; and (5) intellectual property." (3/8/2019)
Has Cytosorbents been receiving favorable news coverage?
News stories about CTSO stock have trended somewhat negative on Thursday, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cytosorbents earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future.
Who are some of Cytosorbents' key competitors?
Some companies that are related to Cytosorbents include Intersect ENT (XENT), Shockwave Medical (SWAV), Cerus (CERS), AngioDynamics (ANGO), OraSure Technologies (OSUR), SurModics (SRDX), Orthopediatrics (KIDS), LeMaitre Vascular (LMAT), Axonics Modulation Technologies (AXNX), Anika Therapeutics (ANIK), Antares Pharma (ATRS), GenMark Diagnostics (GNMK), SI-Bone (SIBN), Inovio Pharmaceuticals (INO) and Accuray (ARAY).
What other stocks do shareholders of Cytosorbents own?
Who are Cytosorbents' key executives?
Cytosorbents' management team includes the folowing people:
- Dr. Phillip P. Chan, CEO, Pres & Director (Age 49)
- Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 64)
- Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 61)
- Dr. Eric R. Mortensen, Chief Medical Officer (Age 59)
- Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 80)
How do I buy shares of Cytosorbents?
Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytosorbents' stock price today?
One share of CTSO stock can currently be purchased for approximately $6.85.
How big of a company is Cytosorbents?
Cytosorbents has a market capitalization of $218.17 million and generates $22.50 million in revenue each year. The medical research company earns $-17,210,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cytosorbents employs 125 workers across the globe.
What is Cytosorbents' official website?
How can I contact Cytosorbents?
Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]
MarketBeat Community Rating for Cytosorbents (NASDAQ CTSO)
MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
